Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor

NCT04316689 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT04316689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04316689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor
Lead sponsor
Shionogi
Phase
Phase 1
Overall status
Completed
Start date
July 30, 2019
Completion date
September 22, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, esophageal cancer, head and neck cancer, lung cancer, mesothelioma